Shareholder alert: brower piven encourages investors who have losses in excess of $100,000 from investment in acelrx pharmaceuticals, inc. to contact brower piven before the december 1, 2014 lead plaintiff deadline in class action lawsuit

Stevenson, md.--(business wire)--the securities litigation law firm of brower piven, a professional corporation, announces that a class action lawsuit has been commenced in the united states district court for the northern district of california on behalf of purchasers of acelrx pharmaceuticals, inc. (“acelrx” or the “company”) (nasdaq: acrx) common stock and/or call options, or sold/wrote acelrx’s put options between december 2, 2013 and september 25, 2014, inclusive (the “class period”). investors who wish to become proactively involved in the litigation have until december 1, 2014 to seek appointment as lead plaintiff. if you have suffered a loss from investment in acelrx securities purchased on or after december 2, 2013 and held through the revelation of negative information during and/or at the end of the class period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. you may also request more information by contacting brower piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. no class has yet been certified in the above action. members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. if you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the court. the lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the class in the action. the lead plaintiff will be selected from among applicants claiming the largest loss from investment in company units during the class period. brower piven also encourages anyone with information regarding the company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. the complaint accuses the defendants of violations of the securities exchange act of 1934 by virtue of the defendants’ failure to disclose during the class period that the instructions for use (ifu) for zalviso (sufentanil sublingual tablet system), formerly known as arx-01, which consists of sufentanil tablets delivered by the zalviso system (collectively, “zalviso”) were not designed to adequately address the risk of the inadvertent misplacement of tablets and that acelrx had not submitted to the u.s. food and drug administration sufficient data to support the shelf life of the product. according to the complaint, following the company’s july 25, 2014 announcement that it had received a complete response letter from fda regarding its nda for zalviso requesting additional data, and the company’s september 26, 2014 disclosure that the resubmission process for its zalviso nda would not be complete until the first quarter of 2015 at the earliest with a review period of six months, the value of acelrx declined significantly. attorneys at brower piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. if you choose to retain counsel, you may retain brower piven without financial obligation or cost to you, or you may retain other counsel of your choice. you need take no action at this time to be a member of the class.
ACRX Ratings Summary
ACRX Quant Ranking